Management of Abnormal Uterine Bleeding and Colposcopy Findings

Initial Evaluation Requirements

The American College of Obstetricians and Gynecologists recommends colposcopy with directed biopsies of all lesions suspected of representing neoplasia after application of 3-5% acetic acid solution, along with endocervical sampling and endometrial sampling for women ≥35 years, to evaluate the endocervical canal and detect potential endometrial pathology 1, 2, 3
Endocervical sampling using either endocervical curette or cytobrush is necessary to evaluate the endocervical canal, as approximately 7% of women ≥35 years with abnormal glandular cells or unexplained bleeding harbor significant endometrial pathology 1, 3, 4

The National Comprehensive Cancer Network recommends that women with colposcopic findings suggesting high-grade squamous intraepithelial lesion (HSIL) or adenocarcinoma in situ (AIS) should undergo diagnostic excisional procedure that provides an intact specimen with interpretable margins, with acceptable excisional procedures including loop electrosurgical excision procedure (LEEP), cold-knife conization, or laser conization 1, 2, 3

The American College of Obstetricians and Gynecologists suggests that HPV testing should be performed if not already obtained, as HPV status is the most important risk stratifier, and women aged 30-65 years with abnormal findings benefit from HPV genotyping, particularly for HPV 16 and 18 1, 6

The American College of Obstetricians and Gynecologists recommends that for HPV-positive patients, repeat cytology combined with HPV DNA testing at 6 months, and for HPV-negative patients, repeat cytology combined with HPV DNA testing at 12 months, with referral back to colposcopy if subsequent HPV testing is positive or cytology shows ASC-US or greater 1, 7

The American College of Obstetricians and Gynecologists suggests that after initial management, the follow-up intensity depends on findings, with CIN 2-3 requiring treatment and subsequent surveillance, HPV-positive patients requiring repeat co-testing at 6 months, and both histology and HPV negative patients requiring repeat co-testing at 12 months 1, 7